Navigation Links
Solutia Reports First Quarter 2009 Results
Date:5/6/2009

ntinuing operations loss of $5 million in the first quarter of 2009 decreased from income of $24 million in the first quarter of last year. This decline was primarily due to the weakened demand profile, higher depreciation and amortization due to fresh-start accounting, and higher stock compensation expense partially offset by income tax benefits. For the quarter, Solutia posted a diluted loss per share from continuing operations of $.04 and as adjusted a loss per share of $.05.

Consolidated EBITDA from continuing operations for the first quarter decreased to $51 million from $73 million in the first quarter of 2008 on net sales of $339 million and $517 million, respectively. After taking into consideration adjustments (as detailed below in the consolidated and segment sales, EBITDA and Adjusted EBITDA table), Adjusted EBITDA decreased to $56 million from $95 million.

"Demand in the first quarter was negatively impacted by the difficult macro-economic conditions affecting the global markets. However, we were able to greatly offset the impact of these conditions through the decisive actions we began to implement in the fourth quarter of last year to reduce our operating costs, working capital levels and capital expenditures. In total, our efforts resulted in an improvement in our liquidity over the course of the first quarter," said Jeffry N. Quinn, chairman, president and chief executive officer of Solutia Inc. "While we expect continued softness in demand throughout 2009, we do expect modest volume improvement in comparison to our first quarter levels. Further, we have taken actions to further reduce costs over the remainder of the year."

Quinn added, "We also are pleased to have closed the $74 million term loan facility at one of our German subsidiaries and we continue to work toward the closure of the sale of our nylon business within the second quarter. These actions will improve our strategic positioni
'/>"/>

SOURCE Solutia Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Solutia to Present at Deutsche Bank Small and Mid Cap Conference
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015 Dr. Robert Hanzlik, ... chemical toxicity carries implications for advancing the creation of ... at National University , the second-largest private, nonprofit ... Dr. Hanzlik, a professor at the University of Kansas ... drug design, starts at 5 p.m. and takes place ...
(Date:4/27/2015)... 27, 2015 Deadly viruses such as ... resident of the University City Science Center's ... , With a $4.5 million Phase 2 SBIR ... Phelix Therapeutics is focused on therapies for ... The company is developing first-in-class protease inhibitors based on ...
(Date:4/27/2015)... -- Editor Note: For more ... . Investor-Edge has initiated coverage on ... LXRX ), Idera Pharmaceuticals Inc. (NASDAQ: IDRA ... Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ), and ... report on Lexicon Pharma can be accessed at ...
(Date:4/27/2015)... 2015 SynGen Inc., a company that focuses ... harvest stem and progenitor cells from umbilical cord blood, ... that it has added three new members to its ... Business Units focus on product commercialization. ... Vice President and Chief Financial Officer.  Chuck was most ...
Breaking Biology Technology:Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5SynGen Inc. Expands Its Management Team 2
... BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer ... for cells and tissues, today announced that it ... cryopreservation media for umbilical cord blood stem cells, ... market. BioLife Solutions, which will be exhibiting at ...
... University say they have discovered a simple method for ... nanostructure that some believe could replace silicon as the ... intense scientific research in recent years, graphene is a ... atoms arranged in a hexagonal lattice. It is the ...
... Drs. Samuel and Elenore Bogoch of BioRadar UK Ltd. announced ... of the EHEC lethal strains of E. Coli preceded the ... have been studied in laboratories in Germany and elsewhere since ... databases. Replikins are subsequences of the genome of an infectious ...
Cached Biology Technology:BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 2BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells 3Northern Illinois University scientists find simple way to produce graphene 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 2Rising Replikin Counts in E. Coli in Germany Since 2005 Preceded Current E. Coli Outbreak 3
(Date:4/14/2015)... 14, 2015  HYPR Corp. today announced it ... ) Alliance tm , an industry consortium transforming ... to share technology and collaborate to deliver open ... more secure and private, and easier to use. ... that protects sensitive user information and eliminates the ...
(Date:4/13/2015)... , April 13, 2015 ... TechSci Research, "Global Biometrics Market Forecast & Opportunities, 2020", ... a CAGR of around 14% till 2020. The ... for large scale implementation and review of biometric ... launch of new products with greater efficiency, are ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... learning more about how protein gets in the urine when ... blocks it. "We have known for a long time ... in diabetes," said Dr. David Pollock, renal physiologist at the ... that a new class of drugs called endothelin A receptor ...
... days of critical international discussion and debate, led by ... Clinical Densitometry (ISCD) and the International Osteoporosis Foundation (IOF), ... pertaining to the interpretation and use of FRAX in ... Tool (FRAX), with models for some 26 countries, is ...
... that applying a stem cell-infused patch together with overexpression ... to damaged cardiac tissue following heart attack and resulted ... also found that function improved more so than when ... that is being studied elsewhere. These findings are ...
Cached Biology News:Scientists learn more about how kidneys fail and how new drugs may intervene 2International discussions on FRAX smooth the way for implementation in clinical practice 2Stem cell patch may result in improved function following heart attack 2Stem cell patch may result in improved function following heart attack 3
... depletion cocktail is tailored to ... from suspensions of rat spleen ... the StemSep (or compatible 0.5 ... system. The CD4+ T cell ...
Preparation TW--Compatibility: Push-on end cap seals suitable up to 70 C only -Hybridization Tube for Model HB-1D -Comp Dim: 200 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-12...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
...
Biology Products: